Research Highlights from the SNMMI 2023 Conference

Designed for theranostic imaging applications, the AnyScan Trio SPECT/CT TheraMax scanner was recently unveiled at the annual meeting of the European Association of Nuclear Medicine (EANM).

Initial detection of metastatic prostate cancer via 68Ga-PSMA-11 PET/CT was significantly associated with PSA values > 20 ng/ml, ISUP grade > 3 and MRI T-stage > 3, according to research presented recently at the SNMMI conference.

Improved assessment of axillary lymph node status with FAPI PET/CT led to restaging of nearly 71 percent of patients with breast cancer, according to new research presented at the SNMMI 2024 conference.

Ultra-low dosing with long axial field-of-view positron emission tomography (PET) scanners facilitates qualitative PET imaging at a more than 50 percent reduction of conventional radiation dosing with PET, according to new research presented at the SNMMI 2024 conference.

Deep transfer learning may elevate the capability of whole-body PET/CT scans to diagnose multiple cancers, ranging from breast cancer and lung cancer to melanoma and prostate cancer, according to new research presented at the SNMMI conference.

In a cohort of 85 patients with biomechanical recurrence of prostate cancer and PSA values less than 2 ng/mL, positive findings on PET imaging with PSMA-18F DCFPyL led to treatment changes in the majority of patients who had negative findings on conventional imaging, according to new research presented at the SNMMI conference.